Could a cheaper dupixent be on the horizon? early trial launches
NCT ID NCT07334496
First seen Jan 12, 2026 · Last updated Jun 22, 2026 · Updated 31 times
Summary
This early-stage trial will test whether a new injection called GLR1044 works like the approved drug Dupixent in the body. About 198 healthy Chinese men will receive a single dose of either GLR1044 or Dupixent. Researchers will compare how the drugs are absorbed and processed, and monitor for any side effects over two months.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BIOSIMILARITY are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing Gobroad Hospital
Beijing, Beijing Municipality, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
GLR1044 injection (a proposed biosimilar to dupilumab)
What this could lead to
If successful, this could lead to a more affordable version of Dupixent for treating conditions like asthma and eczema.
What could go wrong
This is an early phase 1 study in healthy people, not patients. It only checks if the drug behaves similarly, not if it works for any disease. Results may not predict real-world effectiveness.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.